Kidney Cancer Career Enhancement Program (CEP) at DF/HCC
Official title: DF/HCC Kidney Cancer Career Enhancement Program (CEP)
Funded at Beth Israel Deaconess Medical Center · NIH-11421802 · Data updated 2026-11-12
A career-boosting program supports junior investigators studying kidney cancer to help them advance in basic, translational, and clinical work.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 18, 2003 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $322,233 |
| NIH project number | 2P50CA101942-21A1 |
| Project ID | NIH-11421802 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable to patient participants directly; the grant supports investigator development.
✕Less likely to help
Patients will not be enrolled in this grant as participants.
What this research studies
This grant supports a structured mentorship and funding process for rising kidney cancer researchers at the Dana-Farber/DFCI Cancer Institute. It builds on an established track record of helping junior faculty develop careers in kidney cancer science and care. The program uses an administrative core to solicit applicants, select awardees, evaluate progress, and provide mentorship to promote long-term career advancement. The aim is to strengthen leadership in kidney cancer research and improve patient outcomes through translational and clinical work. Participants may receive mentorship, protected time, and resources to pursue impactful projects.
Why it matters
Potential benefit: If successful, this program could accelerate the careers of kidney cancer researchers and ultimately improve treatments and care for patients.
How similar studies have gone: Mentorship- and career-enhancement efforts have historically shown benefits in advancing early-career researchers in oncology.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Kaelin, William G. — Beth Israel Deaconess Medical Center
- Study coordinator: Kaelin, William G.
Related research
Other NIH-funded projects on the same topics.
-
Maximizing anti-tumor immune responses in kidney cancer
A cutting-edge program at UT Southwestern aims to speed up better immunotherapy options for kidney cancer by studying how to activate both innate and adaptive immune responses.
-
Kidney Cancer Development Program at DF/HCC
A funded program at Dana-Farber/Brigham and Women’s Kidney Cancer Center supports new ideas from researchers to improve understanding and treatment of kidney cancer.
-
Personalized antigens for kidney cancer therapy
This grant explores identifying and targeting tumor-specific antigens in kidney cancer to develop more effective, personalized immunotherapies.
-
Optimizing Anti-PD1 Therapy for High-Risk and Metastatic Kidney Cancer
A large cancer research grant is testing how best to use anti-PD-1 therapy to help people with high-risk and metastatic kidney cancer live longer and with fewer side effects.
-
Targeting the HIF2 Pathway in Kidney Cancer
A cancer treatment program aims to see if a drug called belzutifan can help people with a specific kind of kidney cancer whose growth is driven by the HIF2 pathway.
-
Kidney Cancer Tissue Bank and Data Repository Core
A kidney cancer tissue, blood and clinical data repository core aims to collect, store, and organize samples and linked clinical information to support research and improve care for kidney cancer patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.